Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
DexCom
DXCM
5
Collegium Pharmaceutical
COLL
US Stock MarketDetailed Quotes
ICU SeaStar Medical
- 1.6600
- -0.0400-2.35%
Close Mar 31 16:00 ET
14.48MMarket Cap-0.25P/E (TTM)
1.7250High1.6000Low176.75KVolume1.7000Open1.7000Pre Close294.94KTurnover2.05%Turnover RatioLossP/E (Static)8.72MShares20.000052wk High-6.64P/B14.35MFloat Cap1.500052wk Low--Dividend TTM8.64MShs Float550.0000Historical High--Div YieldTTM7.35%Amplitude1.5000Historical Low1.6680Avg Price1Lot Size
Market Insights
Discussing
Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina
Moomoo News Global
Mar 4 23:26
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
SeaStar Medical Stock Forum
SeaStar Medical Achieves Key Milestones: FDA-Approved Therapy Generates Initial Sales
Net revenue for the year ended December 31, 2024, was $0.1 million, compared to no net revenue for the year ended December 31, 2023. The increase in net revenue is due to the initiation of sales of the QUELIMMUNE therapy in the third quarter of 2024, subsequent to its approval in the first quarter by the FDA to commercially sell the QUELIMMUNE pediatric...
No comment yet